Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03341806 · ClinicalTrials.gov registry record · Phase 1
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
A Phase 1 study of Glioblastoma and GBM, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03341806 is a Phase 1 study of Glioblastoma and GBM that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 13 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03341806, a Phase 1 study of Glioblastoma and GBM, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to characterize the safety and tolerability of avelumab in combination with Laser Interstitial Thermal Therapy (LITT) for blood barrier disruption in patients with recurrent glioblastoma.
Conditions Studied
Interventions
- DRUG Avelumab
- COMBINATION_PRODUCT MRI-guided LITT therapy
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-06-13 |
| Est. Completion | 2021-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03341806
The ClinicalTrials.gov registry entry for NCT03341806 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (88% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Avelumab is the first listed.
NCT03341806 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03341806 about?
NCT03341806 is a clinical study titled "Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma". The purpose of the study is to characterize the safety and tolerability of avelumab in combination with Laser Interstitial Thermal Therapy (LITT) for blood barrier disruption in patients with recurrent glioblastoma.
What is the current status of trial NCT03341806?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2018-06-13. Estimated completion is 2021-10-13.
What conditions does trial NCT03341806 study?
This clinical trial studies the following conditions: Glioblastoma, GBM.
What interventions are being tested in trial NCT03341806?
The interventions under investigation include: Avelumab (DRUG), MRI-guided LITT therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03341806?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03341806 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.